

## Optimal COVID-19 quarantine and testing strategies

Chad R. Wells <sup>1\*</sup>, Jeffrey P. Townsend <sup>2,3,4,5\*†</sup>, Abhishek Pandey <sup>1</sup>, Gary Krieger <sup>6</sup>,  
Burton Singer <sup>7</sup>, Robert H. McDonald <sup>8</sup>, Seyed M. Moghadas <sup>9</sup>, Alison P. Galvani <sup>1,3</sup>

<sup>1</sup> *Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, CT 06520, USA*

<sup>2</sup> *Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA*

<sup>3</sup> *Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA*

<sup>4</sup> *Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA*

<sup>5</sup> *Program in Microbiology, Yale University, New Haven, Connecticut 06511, USA*

<sup>6</sup> *NewFields LLC Boulder, CO USA 30301 and Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus*

<sup>7</sup> *Emerging Pathogens Institute, University of Florida, P.O. Box 100009, Gainesville, FL 32610, USA*

<sup>8</sup> *Group Health, Safety and Environment; BHP; Melbourne, Victoria, Australia, 3000*

<sup>9</sup> *Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada*

Keywords: Coronavirus; quarantine; viral shedding; disease control; testing; contact tracing

\*contributed equally to this research

†corresponding author: [Jeffrey.Townsend@Yale.edu](mailto:Jeffrey.Townsend@Yale.edu)

## 28 **Abstract**

29 As economic woes of the COVID-19 pandemic deepen, strategies are being formulated to avoid  
30 the need for prolonged stay-at-home orders, while implementing risk-based quarantine, testing,  
31 contact tracing and surveillance protocols. Given limited resources and the significant economic,  
32 public health and operational challenges of the current 14-day quarantine recommendation, it is  
33 vital to understand if more efficient but equally effective quarantine and testing strategies can be  
34 deployed. To this end, we developed a mathematical model to quantify the probability of post-  
35 quarantine transmission that varied across a range of possible quarantine durations, timings of  
36 molecular testing, and estimated incubation periods. We found that a 13-day quarantine with  
37 testing on entry, a nine-day quarantine with testing on exit, and an eight-day quarantine with  
38 testing on both entry and exit each provide equivalent or lower probability of post-quarantine  
39 transmission compared to a 14-day quarantine with no testing. We found that testing on exit from  
40 quarantine is more effective in reducing probability of post-quarantine transmission than testing  
41 upon entry. When conducting a single test, testing on exit was most effective for quarantines of  
42 six days or shorter, while testing on day six or seven is optimal for longer quarantines. Optimal  
43 timing of testing during quarantine will reduce the probability of post-quarantine transmission, as  
44 false-positive results become less likely, enabling case isolation. Based on 4,040 SARS CoV-2  
45 RT-PCR tests, an exit test 96 hours after the start of quarantine for an offshore oil rig population  
46 was demonstrated to identify all known asymptomatic cases that previously tested negative at  
47 entry, and—moreover—successfully prevented an expected seven or more offshore transmission  
48 events, each a serious concern for initiating rapid spread and a disabling outbreak in the close  
49 quarters of an offshore rig. This successful outcome highlights the importance of context-specific

- 50 guidelines for the duration of quarantine and timing of testing that can minimize economic
- 51 impacts, disruptions to operational integrity, and COVID-related public health risks.

## 52 **Introduction**

53 The COVID-19 pandemic has engendered unprecedented efforts to quell ongoing outbreaks and  
54 manage healthcare capacity, including strict travel restrictions and stay-at-home orders.

55 However, these efforts have disrupted workplaces, leading to significant and pervasive  
56 socioeconomic costs<sup>1,2</sup>. Economic pressures have led many governments and corporations to  
57 proceed with plans to reopen their economy and workforce<sup>3</sup>. Safely reopening in the absence of  
58 a vaccine relies on reducing the likelihood of an infectious individual entering a workplace or  
59 school<sup>4</sup>. Current strategies include the use of a 14-day quarantine and often with some  
60 combination of entry and/or exit testing, coupled with contact tracing should a case arise. These  
61 strategies aim to reduce the effective reproduction number  $R$ —the average number of secondary  
62 infections caused by a primary case—below one.

63  
64 Quarantining individuals imposes myriad challenges for government workers, military,  
65 businesses, universities, and other entities. In many settings, the recommended 14-day quarantine  
66 poses a significant strain on the mental and physical health of employees and their families<sup>5,6</sup>,  
67 coupled with the associated economic toll and potential impacts on operational integrity. For  
68 example, during the time of the epidemic with quarantine measures in place, offshore oil and gas  
69 employees may be needed to work extended cycles significantly beyond their traditional 14-day  
70 on-and-off cycle. This built-in quarantine time into the overall work schedule results in  
71 prolonged time periods that crew members are away from their home. Given the impact of long  
72 quarantines on mental and physical health<sup>5,6</sup>, a priority of our research was to identify a  
73 minimal, effective quarantine strategy for close-quarter environments where there is potentially a  
74 high risk for the rapid spread of COVID-19 with associated severe outcomes and even mortality.

75  
76 Previous work has focused on impact of quarantine and testing on population-level COVID-19  
77 incidence and deaths <sup>7-9</sup>, and testing measures that are most appropriate for disease surveillance  
78 within a population by examining various testing frequencies <sup>10</sup>. Currently, there is no consensus  
79 regarding the optimal duration of quarantine or timing of testing that minimizes the risk of  
80 outbreaks in workplaces, university campuses, military facilities <sup>11</sup>. Many institutions are relying  
81 on testing at entry into quarantine, and other measures such as symptom screenings, hand  
82 sanitizers, and face masks to reduce the risk of an outbreak. Given that over 50% of COVID-19  
83 transmission is attributed to pre-symptomatic and asymptomatic cases <sup>12</sup>, screening for  
84 symptoms alone is inadequate to prevent or interrupt a COVID-19 outbreak <sup>12</sup>. In addition,  
85 testing early post-infection could produce a false-negative result <sup>13</sup>. Thus, symptom-based  
86 screening and one-time testing could still entail a significant probability of post-quarantine  
87 transmission (PQT). Consequently, some jurisdictions have suggested and implemented testing  
88 upon exit from a 14-day quarantine <sup>14</sup>. Understanding the complementarity of quarantine and  
89 testing in reducing PQT would provide vital insight into effective strategies to ensure the safety  
90 of civilian and military workers, students returning to classrooms, and international travelers,  
91 thereby mitigating disease spread in the wider community.

92  
93 Here, we evaluate whether an alternative epidemiologically sound, quarantine and testing  
94 strategy exists that would be equivalent to the standard 14-day quarantine protocol in reducing  
95 PQT. To do so, we developed a mathematical model to calculate the benefits of diverse  
96 quarantine and molecular testing strategies in reducing the probability of PQT, accounting for the  
97 infectivity profile of an infected individual and the temporal diagnostic sensitivity of RT-PCR

98 testing. We estimated the probability of PQT for an infected individual that has not manifested  
99 symptoms but has completed quarantine with undetected infection. In our analysis, we  
100 considered different combinations of timing and frequency of testing with quarantine of up to 14  
101 days, with and without contact tracing. In addition, we performed a sensitivity analysis on our  
102 results based on the impact of differences in the estimated mean incubation period. We compared  
103 the probability of PQT under three scenarios of testing: (i) on entry to quarantine only, (ii) on  
104 exit from quarantine only, and (iii) on both entry to and exit from quarantine for an infected  
105 individual. Lastly, we analyze the results of the application of guidance from our model  
106 regarding the operational processes of quarantine and testing within the oil and gas industry that  
107 prevented offshore transmission (**Supplementary Information: Narrative**).

108

## 109 **Results**

110 Using the infectivity profile derived from transmission pairs of COVID-19 infected individuals  
111 <sup>15</sup>, temporal diagnostic sensitivity of RT-PCR tests <sup>16</sup>, and an incubation period of 8.29 days  
112 (95% credible interval of 7.69–8.92) <sup>17</sup>, we calculated the probability of PQT for a basic  
113 reproduction number of  $R_0 = 2.5$ , assuming that secondary infections are distributed through a  
114 negative binomial distribution with a dispersion parameter of 0.25 <sup>18</sup> (**Table S1**). From the  
115 infectivity profile, assuming that 30.8% of infections are asymptomatic across the disease time  
116 course [12], we estimated that the reproduction number reduces to 1.53 under perfect isolation of  
117 cases upon symptom onset, with 1.09 secondary cases occurring during the incubation period  
118 (**Fig. S1A**). The expected number of secondary infections still remains above one with a lower  
119 asymptomatic proportion of 22.6% or with a reduced  $R_0$  of 2 (**Fig. S1B–D**). Therefore, perfect

120 isolation of all symptomatic individuals would not be sufficient to interrupt the chain of disease  
121 transmission.

122

### 123 *Impact of quarantine without testing*

124 To evaluate the effectiveness of quarantine alone, we computed the expected PQT (**Fig. S2A**)  
125 and the probability of PQT after a range of quarantine durations (**Fig. 1, Fig. S3**). Assuming  
126 individuals self-isolate immediately upon symptom onset, we calculated that the probability of  
127 PQT declines as the duration of quarantine increases (**Fig. 1**). This probability is less than 0.25  
128 with a quarantine duration of at least three days, and falls below 0.05 for quarantines of eight  
129 days or longer.

130

### 131 *Testing during quarantine*

132 The effectiveness of quarantine in reducing the probability of PQT can be augmented through  
133 testing. We assumed a 24-hour delay between the sample collection and test results, indicating  
134 testing on exit occurs a day before the end of quarantine. Under each scenario of testing,  
135 individuals who are tested positive or developed symptoms are isolated. We found that the  
136 probability of PQT is reduced by at least 40.5% across a full range of quarantine durations when  
137 any of the three testing strategies are conducted compared to no testing (**Fig. 1A** and **Fig. S3**).  
138 For a single test during quarantine, testing leads to the largest reduction in the probability of PQT  
139 when it is conducted on the last day of quarantine for durations less than seven days; on day six  
140 for quarantines between seven and 13 days; and on day seven for quarantines 14 days or longer  
141 (**Fig. S4A**).


142

143 Comparing the three testing strategies, we found that testing on both entry and exit from  
144 quarantine provides the greatest return in decreasing the probability of PQT, whereas the benefit  
145 of testing in reducing this probability is lowest when conducted only at entry into quarantine  
146 (**Fig. 1, Fig. S3**). Testing on exit consistently outperformed testing on entry across all quarantine  
147 durations considered (**Fig. 1**). For example, a quarantine duration as short as three days with a  
148 test on both entry and exit yields an 86.1% reduction in probability of PQT relative to no testing,  
149 compared to a 45.5% decrease when the individual is tested on entry only and a 72.9% decline  
150 for testing on exit only (**Fig. S3**).

151

152 We compared strategies of quarantine and testing with the widely implemented, World Health  
153 Organization-recommended 14-day quarantine without testing<sup>19</sup>. We found that a 13-day  
154 quarantine with testing on entry, a nine-day quarantine with testing on exit, and an eight-day  
155 quarantine with testing on both entry and exit each provide equivalent or lower probability of  
156 PQT compared to a 14-day quarantine with no testing (**Fig. 1A, Fig. S2–S3**).

157



**Figure 1:** The probability of post-quarantine transmission for no testing and three testing strategies and durations of quarantine from 1–14 days, with 30.8% asymptomatic infections and perfect self-isolation of symptomatic infections. The average incubation period (specified by a discretized Gamma distribution) of **(A)** 8.29 days (95% credible interval: 7.69–8.92), and **(B)** 5.2 days (95% credible interval: 3.8–6.7). Curves for the probability of post-quarantine transmission show the average probability of one or more post-quarantine infections when an infected individual enters quarantine uniformly within the incubation or asymptomatic period without testing (red), and with testing upon entry to quarantine (orange), on exit from quarantine (blue), and on both entry to and exit from quarantine (purple). With a delay in sample collection to results, we assumed that testing on exit occurred the day before the end of quarantine.


158 *Assessment of quarantine and testing strategies implemented for offshore facilities*

159 We performed an assessment of the practical implications of our analyses based on quarantine  
160 and testing protocols in the setting of offshore oil-and-gas platforms (**Supplementary**  
161 **Information: Narrative**). We stratified the tests into regions A and B based on the location of  
162 the lab where the test results were obtained. Among the 4040 RT PCR tests conducted prior to  
163 travel offshore, there were 69 positive results (1.7%). Initially, a three-day quarantine with  
164 testing only upon entry was implemented. Of the 1792 RT-PCR tests conducted with this  
165 strategy, there were 22 positive results (1.2%). Region A deployed a seven-day home quarantine,  
166 where testing was performed on both entry and exit (96 h after the first test) starting from August  
167 13, with 50.0% (1/2) of the positive tests occurring on exit (**Fig. 2B**). Region B expanded to a  
168 five-day hotel quarantine with testing on both entry and 96 h after the first test, starting on June  
169 25, 2020. For the period in which the entry and exit testing strategy was implemented in region  
170 B, 33.3% (15/45) of the positive tests were obtained upon the exit test, following a negative entry  
171 test (**Fig. 2B**). Further validation of the entry and exit testing protocol was provided through an  
172 additional 155 RT-PCR tests performed post-quarantine (11 days after the initial test), all of  
173 which were negative.

174

175

176



**Figure 2:** Weekly SARS-CoV-2 testing between April 11 to August 26, 2020 among two regions where crew members were quarantined. The positivity rate of test conducted between April 11 and August 26 for (A) region A (with a seven-day quarantine) where testing on entry and exit was started on August 13 and (B) region B (with a five-day quarantine) where testing on entry and exit was started on June 25. Initially, a three-day quarantine with testing only on entry was conducted in both regions. The vertical dashed line separates the strategy of testing on only entry (left), the strategy of testing on both entry and exit (right), with follow-up post-quarantine tests conducted 11 days after the initial test (i.e., on day 12). Negative and positive sequential symbols – and + indicate the test histories. In these results, negative symbols are always conveying results to tests that were previous to the results quantified by the bar above. The number of positive tests and the number of tests conducted is denoted above the bar in parentheses.

177  
 178 No offshore worker registering negative tests-on-entry-and-exit from quarantine was later  
 179 diagnosed with COVID-19 during their offshore work. We quantified the probability of PQT for  
 180 the cases detected by an exit test, as well as the extent to which adding testing on exit to testing  
 181 on entry reduced this probability, assuming an average incubation period of 8.29 days.  
 182 Individuals who eventually developed symptoms entered quarantine uniformly during their  
 183 incubation period (prior to symptom onset), whereas asymptomatic individuals entered  
 184 quarantine over the course of their infection. Compared with a three-day quarantine and testing  
 185 only on entry, extending the quarantine duration and adding testing on exit (96 h after the first  
 186 test) reduced the probability of PQT by 95.3% for the seven-day quarantine and 88.5% for a five-  
 187 day quarantine. If the single case identified on the exit test from region A remained undetected  
 188 within the seven-day quarantine, we estimate an off-shore probability of PQT of 0.127. If the 15  
 189 cases that had been ascertained on exit from region B had remained undetected after the five-day

190 quarantine without testing on exit, we estimate that the probability of PQT would have been  
191 0.982, and would have resulted in an expected 7.2 offshore transmission events—each one a  
192 serious concern for initiating rapid spread and a disabling outbreak in the close quarters of an  
193 offshore rig.. We found that the estimated probability of PQT using the strategy of testing upon  
194 entry and exit moderately increased with the proportion of infections being asymptomatic  
195 (**Fig. S5**).

196

### 197 *Accounting for prevalence of disease in the community.*

198 We evaluated the impact of disease prevalence in the community on the probability of PQT  
199 (**Fig. S6**). For a cohort of size 40 and a five-day quarantine with prevalence of 1%, we estimated  
200 the probability of PQT to be 0.039 for testing only on entry, and 0.006 for testing on both entry  
201 and exit (**Fig. S6B**). For a seven-day quarantine and the same prevalence, the probability of PQT  
202 drops from 0.017 for testing only on entry to 0.002 when augmented with testing on exit  
203 (**Fig. S6C**).

204

### 205 *Contrasting contact tracing and uniform entry into quarantine*

206 We evaluated the effectiveness of quarantine through contact tracing in reducing the probability  
207 of PQT with no delay (**Fig. 3, Fig. S7–S8**) and with one-day delay in the identification of  
208 exposed contacts (**Fig. S9–S10**). Consistent with practices at remote mining sites, tracing of  
209 contacts was assumed to be initiated by the presentation of a worker to the onsite health unit with  
210 relevant COVID-19 symptoms. For offshore oil platforms, contact tracing is initiated if there is  
211 identification of a positive case either by symptom presentation or by surveillance screening  
212 through testing. Rapid contact tracing leads to contacts being quarantined early in the disease

213 time course (if infected), influencing the decline in the probability of PQT as the duration of  
214 quarantine increases compared to uniform entry into quarantine over the duration of the  
215 incubation period or disease course (**Fig. 3** vs **Fig. 1**). Under contact tracing with no testing, the  
216 probability of PQT decreases gradually from 0.32 for a quarantine lasting one day to 0.30 for a  
217 quarantine of three days, then reduces more rapidly to 0.12 for an eight-day quarantine, and  
218 again decreases gradually for longer durations of quarantine (**Fig. 3**). In contrast, entry into  
219 quarantine uniformly over the course of the incubation period or disease period leads to a  
220 continuous decline in the probability of PQT from 0.29 for a one-day quarantine to 0.05 for an  
221 eight-day quarantine, with the rate of decrease slowing for quarantine durations longer than eight  
222 days (**Fig. 1**). We found that the optimal timing of a single test within quarantine of traced  
223 contacts was to test upon exit for durations as long as seven days, with testing on day seven for  
224 quarantines extending beyond seven days (**Fig. S4B**).

225  
226 We observed that the relative decline in the probability of PQT is similar whether entering  
227 quarantine uniformly during infection or through contact tracing. (**Fig. 1** vs **Fig. 3**). However,  
228 when testing on entry, the decrease in the probability of PQT occurring as a consequence of  
229 increasing the duration of quarantine is smaller with contact tracing than with uniform entry into  
230 quarantine. For example, the reductions in the probability of PQT from a one-day quarantine to a  
231 three-day quarantine with testing on entry are 4.1% and 12% for entry into quarantine based on  
232 contact tracing and uniformly, respectively.

233  
234 We found that testing under any of the three strategies (i.e., on entry only, on exit only, or on  
235 both entry and exit) reduces the probability of PQT by at least 30.3% when quarantine is initiated


236 through contact tracing (**Fig. S8**). Furthermore, a 14-day quarantine with no testing is equivalent  
237 to a 13-day quarantine with testing on entry, a nine-day quarantine with testing on exit, and an  
238 eight-day quarantine with testing on entry and exit (**Fig. 3A, Fig. S7–S8**).

239

#### 240 *Effect of the incubation period*

241 We performed a comparative analysis when the average incubation period decreased from 8.29  
242 days<sup>17</sup> to 5.2 days<sup>20</sup>. We found that the difference in the mean incubation period had only a  
243 minimal effect on the expected transmission occurring before symptom onset (1.09 for 8.29 days  
244 vs 1.06 for 5.2 days). The peak of infectivity was slightly higher and earlier with the shorter  
245 incubation period (**Fig. S11**). Entering into quarantine whether uniformly (**Fig. 1B, Fig. S12,**  
246 **Fig. S13**) or through contact tracing (**Fig. 3B, Fig. S14, Fig. S15**), the probability of PQT was  
247 lower for the shorter incubation period. Assuming the shorter incubation period of 5.2 days,  
248 testing on exit is best for quarantines lasting at least four-days (**Fig. S4C, Fig. S4D**). For longer  
249 quarantines, testing on day three was optimal for uniform entry, and on day four when entering  
250 quarantine through contact tracing (**Fig. S4C, Fig. S4D**).

251



**Figure 3:** The probability of post-quarantine transmission for no testing and three testing strategies and durations of quarantine of 1–14 days, with 30.8% asymptomatic infections and perfect self-isolation of symptomatic infections. The average incubation period (specified by a discretized Gamma distribution) of **(A)** 8.29 days (95% credible interval: 7.69–8.92), and **(B)** 5.2 days (95% credible interval: 3.8–6.7). Curves for the probability of post-quarantine transmission show the average probability of one or more post-quarantine infections when an infected individual enters quarantine through contact tracing within the incubation period without testing (red), and with testing upon entry to quarantine (orange), on exit from quarantine (blue), and on both entry to and exit from quarantine (purple). With a delay in sample collection to results, we assumed that testing on exit occurred the day before the end of quarantine

252

253 **Discussion**

254 Here, we developed a modelling framework to calculate the probability of post-quarantine  
255 transmission of COVID-19 for a wide range of durations of quarantine, supplemented by testing  
256 on entry to quarantine, on exit from quarantine, or both. Evidence suggests that isolation of cases  
257 upon symptom onset is insufficient to contain an outbreak of COVID-19<sup>12</sup>. However, the  
258 likelihood of transmission can be reduced substantially through quarantine and testing<sup>4</sup>. We  
259 found that testing on both entry to and exit from quarantine was the most effective strategy in  
260 reducing the probability of PQT. Furthermore, the optimal timing of a single test was upon exit  
261 for quarantines with durations as short as six days. For a quarantine duration longer than six  
262 days, the optimal testing time was between six and seven days.

263

264 The current public health guidelines for a 14-day quarantine of individuals with known exposure  
265 to COVID-19 relies on estimates of 5.2 days for the mean incubation period<sup>20</sup>, indicating that  
266 99% of infected individuals develop symptoms within 14 days of infection. More recent  
267 estimates suggest an extended duration of 20 days from infection to symptom onset, with mean  
268 incubation period of 8.29 days<sup>17</sup>. Monitoring individuals for symptom onset during quarantine is  
269 a suboptimal strategy, as a sizable proportion of individuals experience asymptomatic  
270 infection<sup>21,22</sup>. Furthermore, economic costs and negative effects of a prolonged quarantine on  
271 mental health and other social aspects of life could be substantial. Reducing these consequences  
272 by shortening the duration of quarantine may, on the other hand, increase the risk of post-  
273 quarantine transmission from undetected cases; thus, highlighting the importance of augmenting  
274 quarantine with testing.

275

276 An outbreak can be triggered or sustained within an environment that is monitored only for  
277 symptoms of COVID-19. Quarantining individuals before returning to work or school has been a  
278 common strategy among many businesses, the military and universities to prevent potential  
279 outbreaks. An offshore or military setting is one of numerous close-quarters environments in  
280 modern society where an outbreak can seriously impact operational integrity, leading to  
281 compromised safety and adverse economic consequences. Hence, minimizing outbreak risk  
282 while maintaining staffing is critical. Testing may allow for the quarantine duration to be  
283 reduced without increasing the risk of PQT. For example, many universities have implemented  
284 plans for quarantining and frequent testing of students and employees, where resources allow  
285 <sup>23,24</sup>. For businesses and close-quarters environments, the impact of false negatives are a  
286 substantially greater issue for operational integrity than false positives. Our results show that  
287 testing upon entry to quarantine carries such a risk of false negatives, as infected individuals who  
288 enter quarantine very early in the incubation period of disease may not be detected due to low  
289 viral loads.

290  
291 There are benefits to conducting additional tests as prevalence in the general community  
292 increases (**Fig. S6**, blue and purple), because as substantial numbers of infected individuals enter  
293 quarantine, larger numbers of individuals may proceed through testing with rare false-negative  
294 test results, increasing PQT. Additional tests decrease the likelihood of the occurrence of a series  
295 of false-negatives. However, there is a declining return of additional testing from lower detection  
296 rates during the early stages of disease post-infection (**Fig. S27**). Therefore, the benefit of  
297 additional tests is moderate.  
298

299 Optimal timing of limited testing during quarantine improves the ability to control PQT. Testing  
300 several days into quarantine increases the likelihood of an infected case testing positive  
301 (**Fig. S4**). The increasing diagnostic sensitivity of the RT-PCR test is attributable to the rapidly  
302 increasing viral load following the less detectable latent stage of infection. If the infected  
303 individual remains asymptomatic, testing near the end of a standard 14-day quarantine can also  
304 lead to low diagnostic sensitivity due to a declining viral load as they overcome the infection <sup>25</sup>.  
305 Specifying an average incubation period of 8.29 days, our analysis indicates that the lowest  
306 probability of PQT is achieved by testing on day seven of the standard 14-day quarantine  
307 (**Fig. S4A, Fig S4B**).  
308  
309 Testing was found to result in a smaller reduction of the expected PQT when entering quarantine  
310 through contact tracing compared to not. Contact tracing will be more effective in identifying  
311 infected individuals than when selecting individuals at random for quarantine, due to the  
312 differences in exposure risk, increasing the importance of reducing PQT via testing. For  
313 example, if prevalence is 1% and 10 individuals are selected at random for quarantine, then on  
314 average 0.1 people would be infected. Alternatively, if an index case is isolated upon symptom  
315 onset, there would be on average 1.09 individuals infected (for an  $R_0 = 2.5$ ) prior to symptom  
316 onset and potentially identified through contact tracing. However, individuals entering  
317 quarantine because they are identified by contact tracing are likely to do so earlier post-infection  
318 (**Fig. S28**). Therefore, an earlier entry requires a longer quarantine (generally), and makes it  
319 more likely that testing occurs during the incubation period, when diagnostic sensitivity of the  
320 RT-PCR test is highly limited.  
321

322 Our results are based on the temporal diagnostic sensitivity of RT-PCR tests, which are currently  
323 considered the gold standard test. However, this testing approach is moderately invasive, may be  
324 inconsistent during serial testing, and is dependent on the availability of some raw materials that  
325 have been scarce<sup>26-29</sup>. The use of saliva tests as an alternative could allow for frequent testing of  
326 individuals at a decreased cost, while being less invasive and self-administered<sup>30,31</sup>. There is also  
327 evidence that saliva tests are more sensitive than RT-PCR tests from nasal swabs in COVID-19  
328 patients<sup>26</sup> but less sensitive for detection in a community setting<sup>32</sup>. Thus, the recent innovations  
329 to improve access to testing, such as widespread use of saliva tests, could shift optimal decision-  
330 making for prevention of COVID-19 transmission via quarantine and testing.

331  
332 Our study is informative for businesses, military operations and universities, providing  
333 quantitative estimation of the residual risk of PQT. The calculated infection risks were used to  
334 inform the quarantine and RT-PCR testing strategy deployed by an oil and gas company prior to  
335 workers travelling offshore. Of the positive tests obtained under this strategy, 34% were on the  
336 exit test, which prevented 16 infected crew members that otherwise would have exited  
337 quarantine and entered confined quarters offshore while infectious. The results of the time of  
338 testing for a given quarantine duration could be also useful for population-level disease control  
339 when quarantine is required for international or even interstate travel.

340  
341 Our examination of the effects of durations of quarantine and timings of testing is critical to  
342 future efforts to balance the risk of PQT with the undue costs associated with prolonged  
343 quarantines. As efforts continue for returning to a level of normality, any control strategy will  
344 need to account for public safety, commercial and military operational integrity, school

345 reopening and family emotional well-being. Our study indicates that the approach of testing upon  
346 entry into quarantine—currently implemented by most administrative bodies—is the least  
347 effective strategy. Testing can provide substantially higher dividends in reducing PQT if  
348 performed later during quarantine—at exit, or in longer quarantines, at an optimal timing.  
349 Defining and comprehending the risk of PQT within each context is essential to effective and  
350 transparent balancing of lives and livelihoods in times of a global pandemic.

351

## 352 **Conclusion**

353 Our analysis shows a reduced probability of post-quarantine transmission when testing on exit  
354 compared to testing on entry. By augmenting quarantine with molecular testing, the quarantine  
355 duration can be substantially shortened from the recommended 14-day period, while attaining a  
356 similar level of risk. The results from this analysis are supported by data of quarantined crew  
357 members of an offshore oil facility.

358

## 359 **Methods**

### 360 *Data of SARS CoV-2 tests during quarantine*

361 Between April 11, 2020 and August 26, 2020, there were 4,040 SARS CoV-2 RT-PCR tests  
362 conducted among employees of an oil and gas company coming from two regions (stratified by  
363 lab location). A third region that was monitored is not included in our data set, as there was low  
364 population prevalence entering quarantine and there were no positive tests. During the early  
365 stages of the epidemic, both regions used a three-day quarantine with testing on entry. On  
366 August 13, employees from region A quarantined at home for seven days, with testing occurring  
367 on both entry and exit. While employees were at home, they were asked to practice social

368 distancing in public. Starting on June 25, employees from region B were quarantined in a hotel  
369 for five days prior to their departure off-shore and tested on both entry and exit. The  
370 requirements of an employee to go off-shore were (1) passing the components of a screening  
371 form used to filter out symptomatic cases and those potentially exposed, (2) temperature  
372 screenings, and (3) completion of the quarantine with no positive RT-PCR test. Upon a positive  
373 test, the employee initiated a 14-day isolation period and followed through the company's case  
374 management process. After the isolation period, individuals were able to return back to work  
375 contingent upon two negative RT-PCR tests.

376

### 377 *Epidemiological parameters*

378 The distribution for the average incubation period was assumed to be Gamma distributed, with  
379 an average 8.29 days, and fit to the 95% credible interval of 7.67–8.90<sup>17</sup>. As a sensitivity  
380 analysis to the results, we considered a Gamma distribution with an average of 5.2 days, with the  
381 95% credible interval fit to 4.1–7.0 days<sup>20</sup>. We integrated over these distributions to compute the  
382 expected PQT (average number of secondary infections post-quarantine) and the probability of  
383 PQT associated with each strategy.

384

385 For our baseline analysis, we considered a delay of one day between sample collection and result  
386 of RT-PCT test. Thus, the sample is taken one day before the end of quarantine when testing on  
387 exit. We also conducted the analysis when there was no delay in testing results to examine the  
388 impact on the probability of PQT (**Fig. S16–S19**).

389

390 In the baseline analysis, we assumed  $R_0 = 2.5$  and 30.8% of infections are asymptomatic<sup>12,21</sup>. We  
391 further analyzed the scenario in which 22.6% of infections are asymptomatic (**Fig S20–S23**)<sup>22</sup>.  
392 Asymptomatic infections were assumed to be equally as infectious as symptomatic infections.  
393 This assumption is based on measurements of viral loads in asymptomatic infections being  
394 comparable to those observed in symptomatic cases<sup>33,34</sup>.

395

### 396 *Infectivity profile*

397 We used a Gamma distribution informed by infectivity profiles previously inferred from 77  
398 COVID-19 transmission pairs<sup>15</sup>. For a given incubation period, the parameters of the Gamma  
399 distribution were determined through least squares optimization by fitting the infectivity profile  
400 after symptom onset inferred from the Gamma distribution to the previously estimated infectivity  
401 profiles after symptom onset when infectivity started from five, eight, 11, and 12.3 days prior to  
402 symptom onset. We assumed that the infectivity profile starts upon infection of the individual,  
403 i.e., 12.3 days prior to symptom onset .

404

### 405 *Temporal diagnostic sensitivity of a SARS CoV-2 RT-PCR assay*

406 To account for the variability in viral load dynamics over time, we analyzed the population-  
407 average diagnostic sensitivity at each time point over the course of disease. We incorporated into  
408 our analysis the temporal diagnostic sensitivity results for the RT-PCR tests of infected  
409 individuals over the first month following symptom onset<sup>16</sup>. To infer the diagnostic sensitivity  
410 prior to symptom onset—which was not assessed in Xiao et al<sup>16</sup>, we constructed a mapping  
411 between post-symptom infectivity to the diagnostic sensitivity based on the post-symptomatic  
412 data. This mapping was fit to a sigmoidal Hill function, which fit well the saturating decline in

413 diagnostic sensitivity observed after the incubation period. The parameters for the Hill function  
414 were informed by a least-squares fit to diagnostic sensitivity data for the RT-PCR tests of  
415 infected individuals over the first month following symptom onset<sup>16</sup>. For the fitting of the Hill  
416 function, we used the infectivity profile (as a proxy for the viral load) for an incubation period of  
417 7.76 days (median estimate)<sup>17</sup>. For the fitted case, we checked to ensure that the Hill function  
418 yielded a very similar curve to a more highly parameterized polynomial interpolation function  
419 applied to the temporal diagnostic sensitivity of patients who tested positive after receiving  
420 multiple RT-PCR tests<sup>35</sup>. To specify a single functional form for RT-PCR diagnostic sensitivity,  
421 we then used this mapping from infectivity profile to diagnostic sensitivity to specify diagnostic  
422 sensitivity over the entire course of infection (**Fig. S26**), with similar trends resulting as were  
423 revealed by previous research<sup>10</sup>. We assumed that the specificity of the RT-PCR assay was  
424 100%<sup>36</sup>.

425

#### 426 *Probability of post-quarantine transmission*

427 To calculate the probability of PQT—defined to be the probability of at least one post-quarantine  
428 infection—we assumed that the expected post-quarantine transmission is described by a negative  
429 binomial distribution with a dispersion parameter of 0.25<sup>18</sup>. This value for the dispersion  
430 parameter is consistent with numerous published estimates<sup>37–39</sup>. For sensitivity analyses, we also  
431 computed the probability of PQT given Poisson-distributed post-quarantine transmission  
432 (**Fig. S24–S25**). In our additional analysis accounting for the underlying prevalence within the  
433 community, the probability of PQT was defined as the likelihood that at least one infected  
434 individual in a cohort became a source of PQT. Similarly, to calculate the probability of PQT

435 given a negative test on entry for  $N$  infected individuals, we estimated the probability that at least  
436 one of the cases contributed to PQT.

437

#### 438 **Data availability**

439 The number of positive tests and tests conducted at the two regions quarantining the crew  
440 members heading offshore are presented in **Fig. 2**, with other data used in the analysis referenced  
441 in **Table S1** and in the Methods.

442

#### 443 **Code availability**

444 The computational code for the analysis was implemented in MATLAB, and it is available at  
445 [github.com/WellsRC/Optimizing-COVID19-Quarantine-and-Testing-Strategies](https://github.com/WellsRC/Optimizing-COVID19-Quarantine-and-Testing-Strategies).

446

#### 447 **Acknowledgements:**

448 We thank Justin Abshire for expert data collection. J.P.T. gratefully acknowledges funding from  
449 the National Science Foundation grant CCF 1918656, the Elihu endowment, Notsew Orm Sands  
450 Foundation, and BHP. G.K., B.S., and R.H.M acknowledge funding from BHP. S.M.M.  
451 acknowledges support from the Canadian Institutes of Health Research (grant OV4-170643;  
452 Canadian 2019 Novel Coronavirus Rapid Research), the Natural Sciences and Engineering  
453 Research Council of Canada, and BHP. A.P.G. gratefully acknowledges funding from NIH U01-  
454 GM087719, the Burnett and Stender families' endowment, the Notsew Orm Sands Foundation,  
455 and BHP.

456 **References**

- 457 1. Nicola, M. *et al.* The socio-economic implications of the coronavirus pandemic (COVID-  
458 19): A review. *Int. J. Surg.* **78**, 185–193 (2020).
- 459 2. Martin, A., Markhvida, M., Hallegatte, S. & Walsh, B. Socio-Economic Impacts of  
460 COVID-19 on Household Consumption and Poverty. *Econ Disaster Clim Chang* 1–27  
461 (2020).
- 462 3. Lee, J. C., Mervosh, S., Avila, Y., Harvey, B. & Matthews, A. L. See How All 50 States  
463 Are Reopening (and Closing Again). *The New York Times* (2020).
- 464 4. Aleta, A. *et al.* Modelling the impact of testing, contact tracing and household quarantine on  
465 second waves of COVID-19. *Nature Human Behaviour* **4**, 964–971 (2020).
- 466 5. Brooks, S. K. *et al.* The psychological impact of quarantine and how to reduce it: rapid  
467 review of the evidence. *Lancet* **395**, 912–920 (2020).
- 468 6. Mattioli, A. V., Puviani, M. B., Nasi, M. & Farinetti, A. COVID-19 pandemic: the effects  
469 of quarantine on cardiovascular risk. *Eur. J. Clin. Nutr.* **74**, 852–855 (2020).
- 470 7. Gondim, J. A. M. & Machado, L. Optimal quarantine strategies for the COVID-19  
471 pandemic in a population with a discrete age structure. *Chaos, Solitons & Fractals* vol. 140  
472 110166 (2020).
- 473 8. Cui, Q. *et al.* Dynamic variations of the COVID-19 disease at different quarantine strategies  
474 in Wuhan and mainland China. *J. Infect. Public Health* **13**, 849–855 (2020).
- 475 9. Hou, C. *et al.* The effectiveness of quarantine of Wuhan city against the Corona Virus  
476 Disease 2019 (COVID-19): A well-mixed SEIR model analysis. *J. Med. Virol.* **92**, 841–848  
477 (2020).
- 478 10. Grassly, N. C. *et al.* Comparison of molecular testing strategies for COVID-19 control: a  
479 mathematical modelling study. *Lancet Infect. Dis.* (2020) doi:10.1016/S1473-

- 480 3099(20)30630-7.
- 481 11. Mina, M. J., Parker, R. & Larremore, D. B. Rethinking Covid-19 Test Sensitivity — A  
482 Strategy for Containment. *New England Journal of Medicine* (2020)  
483 doi:10.1056/nejmp2025631.
- 484 12. Moghadas, S. M. *et al.* The implications of silent transmission for the control of COVID-19  
485 outbreaks. *Proc. Natl. Acad. Sci. U. S. A.* (2020) doi:10.1073/pnas.2008373117.
- 486 13. Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in False-  
487 Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2  
488 Tests by Time Since Exposure. *Annals of Internal Medicine* vol. 173 262–267 (2020).
- 489 14. Jung, J. *et al.* The Importance of Mandatory COVID-19 Diagnostic Testing Prior to Release  
490 from Quarantine. *J. Korean Med. Sci.* **35**, (2020).
- 491 15. He, X. *et al.* Author Correction: Temporal dynamics in viral shedding and transmissibility  
492 of COVID-19. *Nat. Med.* (2020) doi:10.1038/s41591-020-1016-z.
- 493 16. Xiao, A. T. *et al.* Dynamic profile of RT-PCR findings from 301 COVID-19 patients in  
494 Wuhan, China: A descriptive study. *J. Clin. Virol.* **127**, 104346 (2020).
- 495 17. Qin, J. *et al.* Estimation of incubation period distribution of COVID-19 using disease onset  
496 forward time: A novel cross-sectional and forward follow-up study. *Sci Adv* **6**, eabc1202  
497 (2020).
- 498 18. Zhang, Y., Li, Y., Wang, L., Li, M. & Zhou, X. Evaluating Transmission Heterogeneity and  
499 Super-Spreading Event of COVID-19 in a Metropolis of China. *Int. J. Environ. Res. Public*  
500 *Health* **17**, (2020).
- 501 19. CDC. When to Quarantine. [https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-](https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html)  
502 [sick/quarantine.html](https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html) (2020).

- 503 20. Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected  
504 Pneumonia. *N. Engl. J. Med.* **382**, 1199–1207 (2020).
- 505 21. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections  
506 (COVID-19). *Int. J. Infect. Dis.* **94**, 154–155 (2020).
- 507 22. Wang, Y. *et al.* Characterization of an Asymptomatic Cohort of Severe Acute Respiratory  
508 Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China.  
509 *Clinical Infectious Diseases* (2020) doi:10.1093/cid/ciaa629.
- 510 23. Matson, Z. College restart nears as students are asked to quarantine. *The Daily Gazette*  
511 (2020).
- 512 24. COVID-19 testing strategies vary widely across institutions.  
513 [https://www.insidehighered.com/news/2020/08/21/covid-19-testing-strategies-vary-widely-](https://www.insidehighered.com/news/2020/08/21/covid-19-testing-strategies-vary-widely-across-institutions)  
514 [across-institutions.](https://www.insidehighered.com/news/2020/08/21/covid-19-testing-strategies-vary-widely-across-institutions)
- 515 25. Sethuraman, N., Jeremiah, S. S. & Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2.  
516 *JAMA* **323**, 2249–2251 (2020).
- 517 26. Wyllie, A. L. *et al.* Saliva is more sensitive for SARS-CoV-2 detection in COVID-19  
518 patients than nasopharyngeal swabs. *medRxiv* 2020.04.16.20067835 (2020).
- 519 27. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*  
520 vol. 581 465–469 (2020).
- 521 28. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected  
522 Patients. *New England Journal of Medicine* vol. 382 1177–1179 (2020).
- 523 29. Wang, W. *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens.  
524 *JAMA* (2020) doi:10.1001/jama.2020.3786.
- 525 30. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a

- 526 cross-sectional study. *Clin. Microbiol. Infect.* (2020) doi:10.1016/j.cmi.2020.05.001.
- 527 31. Nagura-Ikeda, M. *et al.* Clinical Evaluation of Self-Collected Saliva by Quantitative  
528 Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription–Loop-  
529 Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J.*  
530 *Clin. Microbiol.* **58**, (2020).
- 531 32. Becker, D. *et al.* Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection  
532 in the community setting. *medRxiv* 2020.05.11.20092338 (2020).
- 533 33. Li, Y. *et al.* Asymptomatic and Symptomatic Patients With Non-severe Coronavirus  
534 Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A  
535 Retrospective Single Center Study. *Front. Microbiol.* **11**, 1570 (2020).
- 536 34. Lee, S. *et al.* Clinical Course and Molecular Viral Shedding Among Asymptomatic and  
537 Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in  
538 the Republic of Korea. *JAMA Intern. Med.* (2020) doi:10.1001/jamainternmed.2020.3862.
- 539 35. Wikramaratna, P., Paton, R. S., Ghafari, M. & Lourenco, J. Estimating false-negative  
540 detection rate of SARS-CoV-2 by RT-PCR. *medRxiv* 2020.04.05.20053355 (2020).
- 541 36. Dinnes, J. *et al.* Rapid, point-of-care antigen and molecular-based tests for diagnosis of  
542 SARS-CoV-2 infection. *Cochrane Database Syst. Rev.* **8**, CD013705 (2020).
- 543 37. Endo, A., Abbott, S., Kucharski, A. J., Funk, S. & Centre for the Mathematical Modelling  
544 of Infectious Diseases COVID-19 Working Group. Estimating the overdispersion in  
545 COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research* vol.  
546 5 67 (2020).
- 547 38. Website. . [https://assets.researchsquare.com/files/rs-29548/v1\\_stamped.pdf](https://assets.researchsquare.com/files/rs-29548/v1_stamped.pdf).
- 548 39. Bi, Q. *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their

- 549 close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet Infectious*  
550 *Diseases* vol. 20 911–919 (2020).

## Supplementary Information: Optimal COVID-19 quarantine and testing strategies

Chad R. Wells <sup>1\*</sup>, Jeffrey P. Townsend <sup>2,3,4,5\*†</sup>, Abhishek Pandey <sup>1</sup>, Gary Krieger <sup>6</sup>,  
Burton Singer <sup>7</sup>, Robert H. McDonald <sup>8</sup>, Seyed M. Moghadas <sup>9</sup>, Alison P. Galvani <sup>1,3</sup>

<sup>1</sup> *Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, CT 06520, USA*

<sup>2</sup> *Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA*

<sup>3</sup> *Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA*

<sup>4</sup> *Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA*

<sup>5</sup> *Program in Microbiology, Yale University, New Haven, Connecticut 06511, USA*

<sup>6</sup> *NewFields LLC Boulder, CO USA 30301 and Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus*

<sup>7</sup> *Emerging Pathogens Institute, University of Florida, P.O. Box 100009, Gainesville, FL 32610, USA*

<sup>8</sup> *Group Health, Safety and Environment; BHP; Melbourne, Victoria, Australia, 3000*

<sup>9</sup> *Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada*

## **Narrative**

The recommended 14-day quarantine poses a significant strain on the mental health of employees, in addition to bringing economic distress. During the time of the epidemic with quarantine measures in place, employees of an off-shore oil company are working a cycle of 26 days on and 16 days off. The goal of the company has been to reach a risk reduction of a 14-day quarantine through alternative strategies, while considering all factors in play. For the company, the marginal gains in efficacy from a five-day to a seven-day quarantine with testing on entry and exit did not justify its implementation due to the logistical challenges and substantial costs involved. However, quarantine has been chosen to be extended in high-risk areas in order to decrease the risk of an outbreak offshore.

During the early stages of the epidemic, when prevalence was low, a three-day quarantine was implemented by the company in a secured facility with testing occurring on entry. The introduction of the risk reduction models of testing on entry and exit caused a dramatic shift in the decision for quarantining workers. A five-day quarantine was immediately implemented, with testing on entry and the second (exit) test 96 h after the first test. Positive tests were obtained within the first week of testing on exit.

## Theory

### *Transmission over Time*

Infectivity of a pathogen from an infected individual is typically time-dependent, based on pathogen shedding and other factors, and can be represented over time by a function  $r(t)$ , for which time  $t = 0$  represents initial infection, scaled such that

$$\int_{t=0}^{\infty} r(t) t = R_0, \quad (1)$$

where  $R_0$  is the basic reproduction number: the expected number of infections consequent to a single infected individual under a scenario of no intervention. Infectiousness during discrete timespans  $t_2 - t_1$  (e.g. days) can be calculated as

$$R_{t_2-t_1} = \int_{t=t_1}^{t_2} r(t) t.$$

### *Self-isolation at Symptom Onset*

A significant means of intervention to prevent infection is self-isolation of infected individuals upon symptom onset. The expected effect on onward transmission of an intervention such as self-isolation of a case that becomes symptomatic at time  $t_s$  can be calculated as

$$R_i = \int_{t=0}^{t_s} r(t) t, \quad (2)$$

provided that all individuals self-isolate upon presentation with symptoms. If  $\int_{t=0}^{t_s} r(t) t > 1$ , then even perfect self-isolation upon symptom onset will be insufficient to extinguish disease transmission.

If the outcome of infections leads to a proportion of infected individuals  $p_a$  that can infect others but that never manifest symptoms (i.e. that are asymptomatic carriers), then transmission may be partitioned into the contributions of symptomatic and asymptomatic cases as

$R_0 = R_{0,s} p_s + R_{0,a} p_a$ , in which the probability of a symptomatic case  $p_s = (1 - p_a)$ .  $R_{0,s}$  and  $R_{0,a}$  can be equated to distinct infectiousness functions  $r_s(t)$  and  $r_a(t)$ . For simplicity of presentation in ensuing theory, it will be assumed that  $R_{0,s} = R_{0,a}$  and  $r_s(t) = r_a(t) = r(t)$ <sup>1,2</sup>.

Alternate overall transmission and alternate forms of infectivity over time for asymptomatic cases may easily be partitioned and tracked in the theory that follows should there be evidence to substantiate their difference.

With  $R_{0,s} = R_{0,a} = R_0$  and  $r_s(t) = r_a(t) = r(t)$ , the presence of asymptomatic carriers increases the degree of transmission consequent to a self-isolation intervention from that shown by **Eq. 2** to

$$R = p_s \int_{t=0}^{t_s} r(t) t + R_0 p_a .$$

## ***Quarantine***

**Quarantine with a Known Time of Infection.** A longstanding approach to limit disease spread is the quarantine of individuals *who have no prior indication of potential for disease* but intend to migrate from a population in which there is current transmission to a population with lower or zero disease prevalence. Because quarantined individuals experience a significant restriction of personal freedom, it is important to minimize the duration of quarantine  $q$ , but also maximize its effectiveness in limiting post-quarantine transmission. Quarantine of  $q$  days from

time  $t_q$  to time  $t_q + q$  limits total expected post-quarantine transmission to

$$R_q = R_0 - \int_{t_q}^{t_q + q} r(t) t.$$

For policy decision-making regarding quarantine duration, the expected post-quarantine transmission is typically most important, and can be calculated as

$$R_{q \rightarrow} = \int_{t=t_q+q}^{\infty} r(t) t.$$

If individuals self-isolate, there is a trivial case in which  $t_s \leq t_q + q$  and  $R_{q \rightarrow} = 0$ ; otherwise,

$t_s > t_q + q$  and

$$R_{q \rightarrow} = \int_{t=t_q+q}^{t_s} r(t) t.$$

Including asymptomatic carriers,

$$R_{q \rightarrow} = p_s \int_{t=t_q+q}^{t_s} r(t) t + p_a \int_{t=t_q+q}^{\infty} r(t) t.$$

Unfortunately, these expressions are unlikely to be useful in this form for quantifying the benefits of quarantine in reducing transmission. In the case of quarantine of migrants from one population to another, the time of infection—and correspondingly the time of quarantine  $t_q$ —are rarely known.

**Quarantine with an Unknown Time of Infection.** In a rapidly spreading epidemic, individuals who might be entering quarantine will tend to be early in disease time course. In a rapidly declining epidemic, individuals who might be entering quarantine will tend to be later in disease time course. In a steady-state epidemic with case counts  $c(t)$ ,  $\frac{dc}{dt} \approx 0$  over the period from  $t_0$  to  $t_s$  such that individuals entering quarantine are evenly distributed across the disease time

course. Provided all individuals experience symptoms at time  $t_s$  that qualify them for isolation instead of quarantine, then the expected post-quarantine infectivity is

$$r_q(t) = \frac{1}{t_s} \int_{u=0}^{t_s} r(t+u) u,$$

and expected post-quarantine transmission from an infected individual is

$$R_{q \rightarrow}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=u+q}^{\infty} r(t) t u,$$

a function of days of quarantine  $q$ . For asymptomatic carriers entering within disease time course  $t_e$ ,

$$R_{q \rightarrow}(q) = \frac{1}{t_r} \int_{u=0}^{t_e} \int_{t=u+q}^{\infty} r(t) t u.$$

Incorporating both symptomatic and asymptomatic infections,

$$R_{q \rightarrow}(q) = \frac{p_s}{t_s} \int_{u=0}^{t_s} \int_{t=u+q}^{\infty} r(t) t u + \frac{p_a}{t_e} \int_{u=0}^{t_e} \int_{t=u+q}^{\infty} r(t) t u.$$

A similar approach that incorporates symptomatic and asymptomatic cases by their proportions within the population may be performed throughout the rest of the scenarios below, and will not be specifically pointed out for each scenario.

## Testing

**Testing with a Known Time of Infection.** Diagnostic test sensitivity  $s(t)$  is also time-dependent. Assaying for components of the pathogen (e.g. DNA, RNA, or protein), diagnostic sensitivity typically is zero to low very early in disease before the pathogen load burgeons, then declines in the later stages of disease when immune responses develop and infection is suppressed (**Fig. S27**). In a disease for which tests can diagnose infections during the

incubation phase, testing can enhance the efficacy of quarantine by identifying individuals to be isolated instead of quarantined, thereby preventing future transmission from cases that persist as infectious through an earlier exit from quarantine than would be called for in case isolation.

**Testing with an Unknown Time of Infection.** The temporal diagnostic sensitivity of a test for infected cases with an unknown time of infection can be calculated by integrating over the unknown time of infection, such that

$$s_u(t) = \frac{1}{t_e} \int_{u=0}^{t_e} s(t+u) u .$$

### *Quarantine and Testing*

**Quarantine with an Unknown Time of Infection with Testing on Entry.** Assuming the duration of the quarantine,  $q$ , is longer than the delay between administering the test and acting to isolate upon a positive result, the expected post-quarantine infectivity over time of an individual whose time of infection is unknown and who is tested for disease on entry to quarantine is

$$r_{q \rightarrow}(t) = \frac{1}{t_s} \int_{u=0}^{t_s} (1 - s(u)) \cdot r(t+u) u ,$$

in terms of time from infection. In terms of  $q$  days of quarantine, the expected post-quarantine transmission is

$$R_{q \rightarrow}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=q}^{\infty} (1 - s(u)) \cdot r(t+u) t u .$$

For asymptomatic carriers,

$$R_{q \rightarrow}(q) = \frac{1}{t_e} \int_{u=0}^{t_e} \int_{t=q}^{\infty} (1 - s(u)) \cdot r(t+u) t u .$$

### Quarantine with an Unknown Time of Infection with Testing on Entry and Exit.

Expected post-quarantine transmission from an individual whose time of infection is unknown and who is tested for disease upon entry and at the last opportunity prior to the end of quarantine is

$$R_{q^{\rightarrow}}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=q}^{\infty} (1 - s(u)) \cdot (1 - s(u + q - d_t)) \cdot r(t + u) t u ,$$

where  $d_t$  is the delay between administering the test and isolation if positive. For asymptomatic carriers,

$$R_{q^{\rightarrow}}(q) = \frac{1}{t_e} \int_{u=0}^{t_e} \int_{t=q}^{\infty} (1 - s(u)) \cdot (1 - s(u + q - d_t)) \cdot r(t + u) t u .$$

**Quarantine with Testing at Any Time(s).** Expected post-quarantine transmission of an infected individual whose time of infection is unknown and who is tested for disease at any time  $0 \leq t_t \leq q - d_t$  is

$$R_{q^{\rightarrow}}(q) = \frac{1}{t_s} \int_{u=0}^{t_s} \int_{t=q}^{\infty} (1 - s(t_t + u)) \cdot r(t + u) t u .$$

For asymptomatic carriers,

$$R_{q^{\rightarrow}}(q) = \frac{1}{t_e} \int_{u=0}^{t_e} \int_{t=q}^{\infty} (1 - s(t_t + u)) \cdot r(t + u) t u .$$

Additional terms  $(1 - s(u + t_k))$ , where  $k$  indexes testing times, may be included as terms within the product inside the double integral to quantify the expected post-quarantine transmission of any schedule of testing to be applied during quarantine.

**Quarantine with a Negative Test on Entry.** The probability density for obtaining a false negative upon entry for a symptomatic individual is

$$f_S(t) = \begin{cases} \frac{1-s(t)}{\int_{u=0}^{t_s} 1-s(u)du}, & \text{if } 0 \leq t \leq t_S, \text{ and} \\ 0, & \text{otherwise} \end{cases},$$

and the probability density for an asymptomatic individual is

$$f_A(t) = \begin{cases} \frac{1-s(t)}{\int_{u=0}^{t_e} 1-s(u)du}, & \text{if } 0 \leq t \leq t_e, \text{ and} \\ 0, & \text{otherwise.} \end{cases}$$

The expected post-quarantine infectivity over time of a symptomatic individual who tested negative for disease on entry to quarantine is

$$r_{q \rightarrow}(t) = \int_{u=0}^{t_s} f_S(u) \cdot r(t+u) u,$$

in terms of time from infection. In terms of  $q$  days of quarantine, the expected post-quarantine transmission is

$$R_{q \rightarrow}(q) = \int_{u=0}^{t_s} \int_{t=q}^{\infty} f_S(u) \cdot r(t+u) t u.$$

For asymptomatic carriers, the expected post-quarantine infectivity is

$$r_{q \rightarrow}(t) = \int_{u=0}^{t_e} f_A(u) \cdot r(t+u) u,$$

and the expected post-quarantine transmission is

$$R_{q \rightarrow}(q) = \int_{u=0}^{t_e} \int_{t=q}^{\infty} f_A(u) \cdot r(t+u) t u.$$

### **Contact Tracing**

Tracing of individuals who have had contact with an index case identifies persons whose quarantine would reduce the risk of disease transmission from recently exposed individuals.

When an individual is identified as a contact of an index case, the expected time of infection is not the same as that of an individual selected at random from an infected population. Restricting

our attention to transmissions occurring between an index case and their contacts, there are four nominal transmission relationships to be considered, of which three are considered relevant to an attentive program of contact tracing and quarantine (**Table S2**): the asymptomatic or pre-symptomatic contact may have infected the index case, or may have been infected by the index case. Here we excluded from calculation the case in which a pre-symptomatic individual infects the index case, because that scenario is formally impossible with a fixed  $t_s$  and rigorous self-isolation and self-identification upon symptoms, and unlikely even with variable  $t_s$  and imperfect adherence to self-isolation and self-identification.

**Table S2.** Modelled infectivity functions for the contact during tracing.

Contact	Infected by the index case	Infected the index case
Symptomatic case	$r_{I \rightarrow S}(t)$	—
Asymptomatic carrier	$r_{I \rightarrow A}(t)$	$r_{A \rightarrow I}(t)$

**A To-be-Symptomatic Contact Infected by the Index Case but not yet Symptomatic.**

By assumption, infection of the contact must have occurred prior to the onset of symptoms in the index case. The likelihood that an infection from the index case occurred at a time during the disease time course of the index case should proportionally follow  $r(t)$  (**Eq. 1**). Thus, the probability density for infection—on the timescale  $t$  of the infection of the index case that was identified at symptom onset—is

$$\iota(t) = \begin{cases} \frac{r(t)}{\int_{\nu=0}^{t_s} r(s) ds}, & \text{if } 0 \leq t \leq t_s, \text{ and} \\ 0, & \text{otherwise.} \end{cases}$$

The probability density for the time since infection of the to-be-symptomatic contact—on the timescale  $t$  of the contact—is

$$\eta(t) = \mathbf{1}(t_s - t).$$

Thus, the erstwhile expected infectivity from the contact that was infected by the index case from the time of intervention by a quarantine is

$$r_{I \rightarrow S}(t) = \int_{v=d_q}^{t_s} \eta(v) \cdot r(v+t) \, v,$$

where  $d_q$  is the delay from identifying the index case to quarantine of the contact. The expected post-quarantine transmission by the contact after a quarantine of duration  $q$  is

$$R_{I \rightarrow S}_{q \rightarrow}(q) = \int_{v=0}^{t_s} \int_{w=q+d_q}^{t_s} \eta(v) \cdot r(v+w) \, v \, w.$$

**An Asymptomatic Carrier Contact Infected by the Index Case.** The expected infectivity of an asymptomatic contact infected by the index case—from time  $t = 0$  at intervention by quarantine—is

$$r_{I \rightarrow A}(t) = \int_{v=d_q}^{t_s} \eta(v) \cdot r(t+v) \, v,$$

where  $d_q$  is the delay from identifying the index case to quarantine of the contact. The expected post-quarantine transmission from the asymptomatic contact infected by the index case starting from the time of intervention by a quarantine of duration  $q$  is

$$R_{I \rightarrow A}_{q \rightarrow}(q) = \int_{v=0}^{t_s} \int_{w=q+d_q}^{\infty} \eta(v) \cdot r(v+w) \, v \, w.$$

**An Asymptomatic Contact that Infected the Index Case.** Because the index case was assumed to be identified due to symptom onset, an asymptomatic contact that infected the index case must have already been infected for a duration of at least  $t_s + d_q$ . Consequently, the probability density of infection from that contact is

$$\kappa(t) = \begin{cases} \frac{r(t)}{\int_{s=t_S+d_q}^{\infty} r(s)ds}, & \text{if } t \geq t_S + d_q, \text{ and} \\ 0, & \text{otherwise.} \end{cases}$$

Setting  $K = \int_{v=t_S+d_q}^{\infty} r(v) dv$ , the expected infectivity of the asymptomatic contact that infected the symptomatic index case—from time  $t = 0$  at intervention by quarantine—is

$$r_{A \rightarrow I}(t) = \frac{1}{K} \int_{v=t_S+d_q}^{\infty} r(v) \cdot r(t+v) v,$$

and the expected post-quarantine transmission is

$$R_{A \rightarrow I_{q \rightarrow}}(q) = \frac{1}{K} \int_{v=0}^{t_S} \int_{w=t_S+d_q+q}^{\infty} r(v) \cdot r(w+v) v w.$$

Continuing our assumption that individuals are assiduously self-isolating upon symptom onset

and recalling that  $R_i = \int_{t=0}^{t_S} r(t) t$  (**Eq. 2**), we can tabulate the expected transmission by contacts

of the index that are classified into three kinds (**Table S3**). By assumption, a contact to become symptomatic could not have infected the index case, because otherwise in an assiduously self-isolating population, that contact would have been the index case.

**Table S3.** Expected infections from contacts of each modeled transmission type.

Contact	Infected by the index case	Infected the index case
Symptomatic case	$p_s R_i$	—
Asymptomatic carrier	$p_a R_i$	$p_a R_o$

Combining all three transmission functions of contacts of an index case discovered due to appearance of symptoms, the expected post-quarantine infectivity

$$r_c(t) = \frac{p_s R_i}{R_i + p_a R_o} r_{I \rightarrow S}(t) + \frac{p_a R_i}{R_i + p_a R_o} r_{I \rightarrow A}(t) + \frac{p_a R_o}{R_i + p_a R_o} r_{A \rightarrow I}(t).$$

Incorporating a quarantine of duration  $q$  for contacts, the expected post-quarantine transmission

$$R_c(q) = \frac{p_s R_i}{R_i + p_a R_o} R_{I \rightarrow S}(q) + \frac{p_a R_i}{R_i + p_a R_o} R_{I \rightarrow A}(q) + \frac{p_a R_o}{R_i + p_a R_o} R_{A \rightarrow I}(q).$$

### ***Probability of post-quarantine transmission***

The probability of post-quarantine transmission is specified to be the probability that an infected individual exits quarantine, but can still infect one or more individuals. We calculated this probability under a negative-binomial model appropriate when superspreaders play a role in transmission, as well as a Poisson distribution appropriate when transmission is fairly evenly distributed among infected individuals.

**Negative-binomial distribution.** We specified a negative binomial distribution

$$f(x|r,p) = \frac{\Gamma(r+x)}{\Gamma(r)\Gamma(x+1)} p^k (1-p)^x,$$

with dispersion parameter  $k = 0.25^3$  and  $p = \frac{r}{r + R_{q \rightarrow}(q)}$ , such that the average of the distribution was  $R_{q \rightarrow}(q)$ . Thus, the corresponding probability of post-quarantine transmission with negative binomially-distributed transmissions from a case is

$$P(q) = 1 - f(0|k,p).$$

**Poisson distribution.** Specifying a Poisson distribution producing an expected number of secondary infections post-quarantine transmission of  $R_{q \rightarrow}(q)$ , the probability of transmission after a quarantine of duration  $q$  days

$$P(q) = 1 - e^{-R_{q \rightarrow}(q)}.$$

### ***Population prevalence***

Given a cohort size  $N$  and a prevalence of  $\rho$ , the probability of post-quarantine transmission is  $1 - (1 - P(q))^{N\rho}$ .

## ***Methods***

**Infectivity function.** We use a Gamma function to specify the infectivity over the disease time course (**Fig. S1, Fig. S11, and Fig. S26**). The parameters of the Gamma distribution for a given incubation period were estimated by fitting to the post-symptomatic infectivity profile for incubation periods of five, eight, 11, and 12.3 days <sup>4</sup> through minimization of least squares. The infectivity profiles for incubation periods five, eight, 11, and 12.3 days were determined by fitting a Gamma distribution to the digitized data for each incubation period.

**Diagnostic sensitivity function.** We used diagnostic test sensitivity from day one to 30 post-symptom onset <sup>5</sup> and the infectivity profile post-symptom onset <sup>4</sup> to construct a mapping from infectivity to diagnostic sensitivity, in order to infer the diagnostic sensitivity during the incubation period. This mapping from infectivity to diagnostic sensitivity was performed using the Hill function

$$s(t) = \frac{r(t)^n}{r(t)^n + (R_0 C)^n},$$


where  $n$  is the Hill coefficient and  $C$  is the Hill saturation constant.

## Supplementary Tables


**Table S1:** Parameter descriptions and values used to assess quarantine and testing strategies

Description	Parameter	Value	Reference
Basic reproductive number	$R_0$	2.5 and 2.0	6
Basic reproductive number for symptomatic infection	$R_{0,s}$	$R_0$	2
Basic reproductive number for asymptomatic infection	$R_{0,a}$	$R_0$	2
Incubation period	$t_s$	Gamma distribution 8.29 days (95% CI: 7.69–8.92)	7
		Gamma distribution 5.2 days (95% CI: 3.8–6.7)	8
Duration of disease in asymptomatic individuals	$t_e$	$t_s + 20$ days	5
Proportion of infections that are asymptomatic	$p_a$	30.8%	9
		22.6%	10
Saturation constant for sensitivity function	$C$	0.26	Estimated
Hill coefficient for the sensitivity function	$n$	$3 \times 10^{-5}$	Estimated


## Supplementary Figures



**Figure S1.** Average infectivity profile for a known time of infection under no self-isolation upon symptom onset (black) and perfect isolation upon symptom onset (yellow line) for (A)  $R_0 = 2.5$  and 30.8% infections being asymptomatic (resulting in 1.53 secondary infections, yellow fill), (B)  $R_0 = 2$  and 30.8% infections being asymptomatic (resulting in 1.22 secondary infections, yellow fill), (C)  $R_0 = 2.5$  and 22.6% infections being asymptomatic (resulting in 1.41 secondary infections, yellow fill) and (D)  $R_0 = 2$  and 22.6% infections being asymptomatic (resulting in 1.13 secondary infections, yellow fill).




**Figure S2:** Expected post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S3:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate


equivalent durations of quarantine associated with each of the testing strategies.




**Figure S4:** The optimal day of testing to obtain the minimum post-quarantine transmission with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of (A) 8.29 days and a 95% credible interval of 7.69–8.92 days and uniform entry into quarantine, (B) 8.29 days (95% CI: 7.69–8.92 days) and entry into quarantine as a traced contact, (C) 5.2 days (95% CI: 3.8–6.7 days) and uniform entry into quarantine, (D) 5.2 days (95% CI: 3.8–6.7 days) and entry into quarantine as a traced contact.




**Figure S5:** The impact of asymptomatic infection on the probability of post-quarantine transmission, with perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for proportions from 0–1 of infections being asymptomatic, the average probability of post-quarantine transmission (probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing (red) and when tested on entry and exit from quarantine (blue) for a **(A)** five-day quarantine and a **(B)** seven-day quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete.




**Figure S6.** The probability of post-quarantine transmission for a cohort and underlying prevalence. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, the probability of post-quarantine transmission accounting for underlying community prevalence in a cohort (crew) of 40 employees for testing on entry (orange), testing on exit (blue), and testing on both entry and exit (purple) for a (A) three-day quarantine, (B) five-day quarantine, (C) seven-day quarantine, and (D) 14-day quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete.




**Figure S7:** Secondary infections post-quarantine when entering quarantine through contact tracing for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when individuals enter quarantine through contact tracing with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete.



**Figure S8:** Probability of post-quarantine transmission when entering quarantine through contact tracing for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S9:** Secondary infections post-quarantine when entering quarantine through contact tracing, with a one-day tracing delay, for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when individuals enter quarantine one day after being identified through contact tracing with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S10:** Probability of post-quarantine transmission when entering quarantine through contact tracing, with a one-day tracing delay, for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine after one day from being identified through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the

testing strategies.




**Figure S11: Average infectivity profile for two reported durations of the incubation period.**

Average infectivity of an infected individual under no self-isolation upon symptom onset where the average incubation period is 8.29 days (black) and 5.2 days (dashed green line). The number of secondary infections that occur with an incubation period of 8.29 days is 1.09, and with an incubation period of 5.2 days is 1.06.




**Figure S12:** Secondary infections post-quarantine when entering quarantine not through contact tracing for an average incubation period of 5.2 days. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 5.2 days and a 95% credible interval of 3.8–6.7 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S13:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 5.2 days. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 5.2 days and a 95% credible interval of 3.8–6.7 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine


associated with each of the testing strategies.




**Figure S14:** Secondary infections post-quarantine when entering quarantine through contact tracing for an average incubation period of 5.2 days. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 5.2 days and a 95% credible interval of 3.8–6.7 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when individuals enter quarantine through contact tracing with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.



**Figure S15:** Probability of post-quarantine transmission when entering quarantine through contact tracing for an average incubation period of 5.2 days. Impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 5.2 days and a 95% credible interval of 3.8–6.7 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S16:** Secondary infections post-quarantine when entering quarantine not through contact tracing for an average incubation period of 8.29 days and no delay in obtaining the test result. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Testing on exit is assumed to occur on the last day of quarantine (i.e. there is negligible delay in obtaining the test result). Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S17:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days, with no delay in obtaining test results. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Testing on exit is assumed to occur on the last day of quarantine (i.e. there is negligible delay in obtaining the test result). Cells that share a background color in common indicate equivalent


durations of quarantine associated with each of the testing strategies.




**Figure S18:** Secondary infections post-quarantine when entering quarantine through contact tracing for an average incubation period of 8.29 days and no delay in obtaining the test result. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when a symptomatic individual enters quarantine through contact tracing with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Testing on exit is assumed to occur on the last day of quarantine (i.e. there is negligible delay in obtaining the test result). Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies



**Figure S19:** Probability of post-quarantine transmission when entering quarantine through contact tracing for an average incubation period of 8.29 days, with no delay in obtaining the test result. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Testing on exit is assumed to occur on the last day of quarantine (i.e. there is negligible delay in obtaining the test result). Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S20:** Secondary infections post-quarantine when entering quarantine not through contact tracing for an average incubation period of 8.29 days and fewer asymptomatic infections. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 22.6% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine from 1–21 days, **(A)** the average number of expected infections post-quarantine when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, testing on entry, testing on exit, and testing on entry and exit, when tested on exit from quarantine, and when tested on entry and exit from quarantine; and **(B)** durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S21:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 22.6% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate


equivalent durations of quarantine associated with each of the testing strategies.



**Figure S22:** Secondary infections post-quarantine when entering quarantine through contact tracing for an average incubation period of 8.29 days and fewer asymptomatic infections. The impact of quarantine and testing on reducing secondary infections post-quarantine, with 22.6% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days for durations of quarantine of 1–21 days, **(A)** the average number of expected infections post-quarantine when individuals enter quarantine through contact tracing with no testing, testing on entry, testing on exit, and testing on entry and exit; and **(B)** the durations of quarantine with testing on entry, testing on exit, and testing on entry and exit that perform just as well or better than a quarantine with no testing. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S23:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days, with fewer asymptomatic infections. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 22.6% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S24:** Probability of post-quarantine transmission when entering quarantine not through contact tracing for an average incubation period of 8.29 days, assuming transmission is Poisson distributed. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with 30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine

(probability of one or more post-quarantine infections) when a symptomatic individual enters quarantine uniformly within the incubation period and asymptomatic individuals enter uniformly across the disease time course with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.




**Figure S25:** Probability of post-quarantine transmission when entering quarantine through contact tracing for an average incubation period of 8.29 days, assuming transmission is Poisson distributed. The impact of quarantine and testing on reducing the probability of post-quarantine transmission, with


30.8% of infections asymptomatic and perfect self-isolation of symptomatic infections. Specifying an incubation period using a discretized Gamma distribution for the incubation period with an average of 8.29 days and a 95% credible interval of 7.69–8.92 days, for durations of quarantine from 1–21 days, the average probability of ongoing transmission post-quarantine (probability of one or more post-quarantine infections) when individuals enter quarantine through contact tracing with no testing, when tested upon entry to quarantine, when tested on exit from quarantine, and when tested on entry and exit from quarantine. Because of the time required to obtain test results, sampling for the test on exit is assumed to occur the day before the quarantine is complete. Cells that share a background color in common indicate equivalent durations of quarantine associated with each of the testing strategies.



**Figure S26:** The infectivity profile over the time course of disease for incubation periods of 5.2 days (blue), 7.76 days (black), 8.29 days (green), and 14 days (yellow).



**Figure S27:** The diagnostic sensitivity of the RT-PCR test over the time course of disease. **(A)** The infectivity function using an incubation period of 7.76 days (median estimate)<sup>7</sup> was mapped to the diagnostic sensitivity using a sigmoidal Hill function (black line) fit to the empirical data of SARS CoV-2 test results from Xiao, A. T. et al.<sup>5</sup> (red dots) through minimization of least squares. **(B)** The daily diagnostic sensitivity for an incubation period of 5.2 days (blue), 8.29 days (green), and 14 days (yellow) over the course of the disease.



**Figure S28:** The probability density function for when during the disease time course cases enter quarantine. **(A)** The day in which a contact infected by an index case enters quarantine (black) compared to the uniform entry into quarantine of a case to exhibit symptoms (blue) and an asymptomatic case (red). **(B)** The day in which the asymptomatic contact that infected the index case enters quarantine (black) compared to the uniform entry of an asymptomatic case (red) entering quarantine.

## References

1. Li, Y. *et al.* Asymptomatic and Symptomatic Patients With Non-severe Coronavirus Disease (COVID-19) Have Similar Clinical Features and Virological Courses: A Retrospective Single Center Study. *Front. Microbiol.* 11, 1570 (2020).
2. Lee, S. *et al.* Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. *JAMA Intern. Med.* (2020) doi:10.1001/jamainternmed.2020.3862.
3. Zhang, Y., Li, Y., Wang, L., Li, M. & Zhou, X. Evaluating Transmission Heterogeneity and Super-Spreading Event of COVID-19 in a Metropolis of China. *Int. J. Environ. Res. Public Health* 17, (2020).
4. He, X. *et al.* Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* (2020) doi:10.1038/s41591-020-1016-z.
5. Xiao, A. T. *et al.* Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study. *J. Clin. Virol.* 127, 104346 (2020).
6. Moghadas, S. M. *et al.* Projecting hospital utilization during the COVID-19 outbreaks in the United States. *Proc. Natl. Acad. Sci. U. S. A.* 117, 9122–9126 (2020).
7. Qin, J. *et al.* Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. *Sci Adv* 6, eabc1202 (2020).
8. Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N. Engl. J. Med.* 382, 1199–1207 (2020).
9. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int. J. Infect. Dis.* 94, 154–155 (2020).

10. Wang, Y. *et al.* Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China. *Clinical Infectious Diseases* (2020) doi:10.1093/cid/ciaa629.